Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Savannah, GA
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Lexington, KY
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Baltimore, MD
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Springfield, MA
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Saginaw, MI
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Saginaw, MI
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Rochester, MN
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Jackson, MS
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
St. Louis, MO
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Grand Island, NE
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Grand Island, NE
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Mount Laurel, NJ
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Mount Laurel, NJ
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Bronx, NY
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Bronx, NY
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Cincinnati, OH
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Oklahoma City, OK
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Philadelphia, PA
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Providence, RI
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Orangeburg, SC
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Galveston, TX
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Galveston, TX
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Fairfax, VA
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Fairfax, VA
Click here to add this to my saved trials
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated:  3/25/2013
Otsuka Investigational Site
mi
from
Madison, WI
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia
Status: Enrolling
Updated: 3/25/2013
Otsuka Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Establishment of Biomarkers for Fabry Disease
Establishment of Biomarkers for Fabry Disease
Status: Enrolling
Updated:  5/20/2013
Eye and Ear Institute
mi
from
Columbus, OH
Establishment of Biomarkers for Fabry Disease
Establishment of Biomarkers for Fabry Disease
Status: Enrolling
Updated: 5/20/2013
Eye and Ear Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Neurobehavioral Phenotypes in MPS III
Characterizing the Neurobehavioral Phenotype(s) in MPS III
Status: Enrolling
Updated:  6/5/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Neurobehavioral Phenotypes in MPS III
Characterizing the Neurobehavioral Phenotype(s) in MPS III
Status: Enrolling
Updated: 6/5/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Psychological Concomitants of Morquio Syndrome (The MAP Study)
Psychological Concomitants of Morquio Syndrome
Status: Enrolling
Updated:  7/23/2013
Emory University
mi
from
Atlanta, GA
Psychological Concomitants of Morquio Syndrome (The MAP Study)
Psychological Concomitants of Morquio Syndrome
Status: Enrolling
Updated: 7/23/2013
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bioavailability of EPA and DHA From Two Dietary Supplements
A Randomized, Controlled, Crossover Study to Evaluate the Acute and Subchronic Bioavailability of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) From Two Dietary Supplements in Men and Women With Mildly Elevated Triglycerides
Status: Enrolling
Updated:  7/23/2013
Biofortis
mi
from
Addison, IL
Bioavailability of EPA and DHA From Two Dietary Supplements
A Randomized, Controlled, Crossover Study to Evaluate the Acute and Subchronic Bioavailability of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) From Two Dietary Supplements in Men and Women With Mildly Elevated Triglycerides
Status: Enrolling
Updated: 7/23/2013
Biofortis
mi
from
Addison, IL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Farmville Internal Medicine
mi
from
Farmville, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Farmville Internal Medicine
mi
from
Farmville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Mark R. Cervi
mi
from
Greenville, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Mark R. Cervi
mi
from
Greenville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Physicians East, Quadrangle Medical Specialists
mi
from
Greenville, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Physicians East, Quadrangle Medical Specialists
mi
from
Greenville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Carolina East Family Medicine
mi
from
Greenville, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Carolina East Family Medicine
mi
from
Greenville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Eastern Carolina Physicians
mi
from
Kinston, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Eastern Carolina Physicians
mi
from
Kinston, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated:  8/12/2013
Natalie A Doyle, MD PA
mi
from
Wilson, NC
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia
Status: Enrolling
Updated: 8/12/2013
Natalie A Doyle, MD PA
mi
from
Wilson, NC
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Muscle Shoals, AL
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Los Angeles, CA
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Jacksonville, FL
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Miami, FL
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Winter Park, FL
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Winter Park, FL
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Kansas City, KA
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Louisville, KY
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Auburn, ME
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Auburn, ME
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Raleigh, NC
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Raleigh, NC
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated:  9/13/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)
Status: Enrolling
Updated: 9/13/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
Yale University School of Medicine
mi
from
New Haven, CT
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
Clinical Research Center, Indiana University School of Medicine
mi
from
Indianapolis, IN
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
Clinical Research Center, Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
Duke Clinical Research Unit
mi
from
Durham, NC
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
Duke Clinical Research Unit
mi
from
Durham, NC
Click here to add this to my saved trials
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
University of California - San Francisco
mi
from
San Francisco, CA
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
Yale University School of Medicine
mi
from
New Haven, CT
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
Clinical Research Center, Indiana University School of Medicine
mi
from
Indianapolis, IN
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
Clinical Research Center, Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials